OR WAIT null SECS
August 17, 2021
Syngene’s additions include a new microbial facility and an expanded mammalian facility.
Primates inoculated with CV2CoV show improved immune response and protection from various COVID variants.
FDA has granted its first approval for an idiopathic hypersomnia treatment.
Biotage’s new facility in Cardiff, UK, will produce lipids using large-scale flash purification.
August 16, 2021
FDA has opened a public docket soliciting feedback on the regulation process surrounding PANDAs.
August 13, 2021
Terumo Blood and Cell Technologies and PhotonPharma announced a collaboration to develop a novel tumor-specific immunotherapy for solid tumors.
PNI expands global headquarters with a new 75,000-square-foot facility, which will include multiple GMP suites for manufacturing RNA therapeutics and vaccines.
The companies announce the results of a research collaboration that applied machine learning to significantly advance the scalability of spirulina-based biologic drugs.
Eli Lilly and Company and Incyte have announced promising results that patients with COVID-19 on mechanical ventilation saw a reduction in deaths with the addition of baricitinib treatment.
Almac Sciences has signed a manufacturing agreement with Pila Pharma for the production of the API XEN-D0501.